Does the media favor NAGE or SVRA?

In the previous week, Savara had 3 more articles in the media than Niagen Bioscience. MarketBeat recorded 5 mentions for Savara and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 0.93 beat Savara's score of 0.69 indicating that Niagen Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, AKTS or NAGE?

Niagen Bioscience has higher revenue and earnings than Aktis Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aktis Oncology $6.50M 178.93 N/A N/A N/A Niagen Bioscience $129.42M 2.17 $17.38M $0.21 16.81

Does the media favor AKTS or NAGE?

In the previous week, Aktis Oncology had 2 more articles in the media than Niagen Bioscience. MarketBeat recorded 4 mentions for Aktis Oncology and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 0.93 beat Aktis Oncology's score of 0.47 indicating that Niagen Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Niagen Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NAGE or XERS?

In the previous week, Xeris Biopharma had 5 more articles in the media than Niagen Bioscience. MarketBeat recorded 7 mentions for Xeris Biopharma and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 0.93 beat Xeris Biopharma's score of 0.26 indicating that Niagen Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, NAGE or EVO?

Niagen Bioscience has higher earnings, but lower revenue than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Niagen Bioscience $129.42M 2.17 $17.38M $0.21 16.81 Evotec $891.97M 1.12 -$117.12M N/A N/A

Is NAGE or EVO more profitable?

Niagen Bioscience has a net margin of 14.29% compared to Evotec's net margin of -26.20%. Niagen Bioscience's return on equity of 22.68% beat Evotec's return on equity. Company Net Margins Return on Equity Return on Assets Niagen Bioscience 14.29% 22.68% 16.23% Evotec -26.20% -24.93% -11.35%

Does the media favor NAGE or EVO?

In the previous week, Evotec had 1 more articles in the media than Niagen Bioscience. MarketBeat recorded 3 mentions for Evotec and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 0.93 beat Evotec's score of 0.91 indicating that Niagen Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NAGE or CRON?

In the previous week, Cronos Group had 1 more articles in the media than Niagen Bioscience. MarketBeat recorded 3 mentions for Cronos Group and 2 mentions for Niagen Bioscience. Cronos Group's average media sentiment score of 1.19 beat Niagen Bioscience's score of 0.93 indicating that Cronos Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cronos Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Niagen Bioscience (NAGE) Competitors

$3.52 +0.08 (+2.17%)

As of 10:05 AM Eastern

Compare

NAGE vs. SVRA, AKTS, XERS, EVO, and CRON

Should you buy Niagen Bioscience stock or one of its competitors? MarketBeat compares Niagen Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Niagen Bioscience include Savara (SVRA), Aktis Oncology (AKTS), Xeris Biopharma (XERS), Evotec (EVO), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry.

How does Niagen Bioscience compare to Savara?

Niagen Bioscience (NASDAQ:NAGE) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Niagen Bioscience has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, Savara has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

Niagen Bioscience has a net margin of 14.29% compared to Savara's net margin of 0.00%. Niagen Bioscience's return on equity of 22.68% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
Savara	N/A	-87.19%	-66.42%

Niagen Bioscience has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	2.17	$17.38M	$0.21	16.81
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

In the previous week, Savara had 3 more articles in the media than Niagen Bioscience. MarketBeat recorded 5 mentions for Savara and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 0.93 beat Savara's score of 0.69 indicating that Niagen Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Niagen Bioscience currently has a consensus price target of $10.50, indicating a potential upside of 197.45%. Savara has a consensus price target of $10.14, indicating a potential upside of 84.42%. Given Niagen Bioscience's higher probable upside, research analysts plainly believe Niagen Bioscience is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Niagen Bioscience beats Savara on 11 of the 16 factors compared between the two stocks.

How does Niagen Bioscience compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Niagen Bioscience has a net margin of 14.29% compared to Aktis Oncology's net margin of 0.00%. Niagen Bioscience's return on equity of 22.68% beat Aktis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Niagen Bioscience	14.29%	22.68%	16.23%

In the previous week, Aktis Oncology had 2 more articles in the media than Niagen Bioscience. MarketBeat recorded 4 mentions for Aktis Oncology and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 0.93 beat Aktis Oncology's score of 0.47 indicating that Niagen Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Niagen Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Niagen Bioscience has higher revenue and earnings than Aktis Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	178.93	N/A	N/A	N/A
Niagen Bioscience	$129.42M	2.17	$17.38M	$0.21	16.81

28.8% of Aktis Oncology shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aktis Oncology currently has a consensus target price of $32.50, suggesting a potential upside of 49.22%. Niagen Bioscience has a consensus target price of $10.50, suggesting a potential upside of 197.45%. Given Niagen Bioscience's higher possible upside, analysts plainly believe Niagen Bioscience is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Niagen Bioscience beats Aktis Oncology on 7 of the 12 factors compared between the two stocks.

How does Niagen Bioscience compare to Xeris Biopharma?

Niagen Bioscience (NASDAQ:NAGE) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Niagen Bioscience has a net margin of 14.29% compared to Xeris Biopharma's net margin of 3.81%. Xeris Biopharma's return on equity of 735.00% beat Niagen Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
Xeris Biopharma	3.81%	735.00%	3.24%

Niagen Bioscience currently has a consensus price target of $10.50, suggesting a potential upside of 197.45%. Xeris Biopharma has a consensus price target of $10.80, suggesting a potential upside of 58.71%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Niagen Bioscience is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by company insiders. Comparatively, 4.4% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Xeris Biopharma had 5 more articles in the media than Niagen Bioscience. MarketBeat recorded 7 mentions for Xeris Biopharma and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 0.93 beat Xeris Biopharma's score of 0.26 indicating that Niagen Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xeris Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Niagen Bioscience has higher earnings, but lower revenue than Xeris Biopharma. Niagen Bioscience is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	2.17	$17.38M	$0.21	16.81
Xeris Biopharma	$291.85M	4.03	$550K	$0.06	113.42

Niagen Bioscience has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Summary

Niagen Bioscience beats Xeris Biopharma on 9 of the 16 factors compared between the two stocks.

How does Niagen Bioscience compare to Evotec?

Niagen Bioscience (NASDAQ:NAGE) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Niagen Bioscience presently has a consensus target price of $10.50, suggesting a potential upside of 197.45%. Evotec has a consensus target price of $7.00, suggesting a potential upside of 148.67%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Niagen Bioscience is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Niagen Bioscience has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, Evotec has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market.

Niagen Bioscience has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	2.17	$17.38M	$0.21	16.81
Evotec	$891.97M	1.12	-$117.12M	N/A	N/A

Niagen Bioscience has a net margin of 14.29% compared to Evotec's net margin of -26.20%. Niagen Bioscience's return on equity of 22.68% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
Evotec	-26.20%	-24.93%	-11.35%

In the previous week, Evotec had 1 more articles in the media than Niagen Bioscience. MarketBeat recorded 3 mentions for Evotec and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 0.93 beat Evotec's score of 0.91 indicating that Niagen Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Niagen Bioscience beats Evotec on 11 of the 14 factors compared between the two stocks.

How does Niagen Bioscience compare to Cronos Group?

Niagen Bioscience (NASDAQ:NAGE) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Niagen Bioscience has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, Cronos Group has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by insiders. Comparatively, 7.8% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Niagen Bioscience has a net margin of 14.29% compared to Cronos Group's net margin of -1.14%. Niagen Bioscience's return on equity of 22.68% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
Cronos Group	-1.14%	-1.26%	-1.20%

Niagen Bioscience currently has a consensus price target of $10.50, indicating a potential upside of 197.45%. Cronos Group has a consensus price target of $2.30, indicating a potential downside of 14.66%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, research analysts clearly believe Niagen Bioscience is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cronos Group	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Cronos Group had 1 more articles in the media than Niagen Bioscience. MarketBeat recorded 3 mentions for Cronos Group and 2 mentions for Niagen Bioscience. Cronos Group's average media sentiment score of 1.19 beat Niagen Bioscience's score of 0.93 indicating that Cronos Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cronos Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Niagen Bioscience has higher earnings, but lower revenue than Cronos Group. Niagen Bioscience is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	2.17	$17.38M	$0.21	16.81
Cronos Group	$146.59M	6.86	-$9.45M	$0.01	269.50

Summary

Niagen Bioscience beats Cronos Group on 10 of the 15 factors compared between the two stocks.

Get Niagen Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAGE vs. The Competition

Export

Metric	Niagen Bioscience	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$280.81M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	16.79	20.00	24.00	24.42
Price / Sales	2.17	303.75	533.77	123.88
Price / Cash	17.01	53.61	27.48	37.92
Price / Book	3.68	8.32	10.55	6.82
Net Income	$17.38M	$23.94M	$3.57B	$337.56M
7 Day Performance	4.75%	1.84%	0.59%	1.16%
1 Month Performance	-3.29%	-0.04%	1.55%	3.16%
1 Year Performance	-74.10%	44.82%	25.41%	30.60%

Niagen Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAGE Niagen Bioscience	4.3386 of 5 stars	$3.53 +2.3%	$10.50 +197.5%	-74.7%	$280.81M	$129.42M	16.79	120
SVRA Savara	2.0655 of 5 stars	$5.37 +2.4%	$10.14 +88.7%	+138.0%	$1.10B	N/A	N/A	20	Analyst Upgrade
AKTS Aktis Oncology	1.9375 of 5 stars	$20.51 +5.9%	$32.50 +58.5%	N/A	$1.10B	$6.50M	N/A	76	Gap Down
XERS Xeris Biopharma	3.019 of 5 stars	$6.16 +4.5%	$10.80 +75.5%	+56.1%	$1.06B	$291.85M	102.58	290	Gap Up
EVO Evotec	2.3666 of 5 stars	$2.95 +2.1%	$7.00 +137.3%	-36.3%	$1.05B	$891.97M	N/A	4,553

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAGE) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Niagen Bioscience (NAGE) Competitors

NAGE vs. SVRA, AKTS, XERS, EVO, and CRON

How does Niagen Bioscience compare to Savara?

Summary

How does Niagen Bioscience compare to Aktis Oncology?

Summary

How does Niagen Bioscience compare to Xeris Biopharma?

Summary

How does Niagen Bioscience compare to Evotec?

Summary

How does Niagen Bioscience compare to Cronos Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAGE vs. The Competition

Niagen Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Niagen Bioscience (NAGE) Competitors

NAGE vs. SVRA, AKTS, XERS, EVO, and CRON

How does Niagen Bioscience compare to Savara?

Do institutionals and insiders have more ownership in NAGE or SVRA?

Which has more risk & volatility, NAGE or SVRA?

Is NAGE or SVRA more profitable?

Which has stronger earnings & valuation, NAGE or SVRA?

Does the media favor NAGE or SVRA?

Do analysts recommend NAGE or SVRA?

Summary

How does Niagen Bioscience compare to Aktis Oncology?

Is AKTS or NAGE more profitable?

Does the media favor AKTS or NAGE?

Which has better valuation and earnings, AKTS or NAGE?

Do institutionals & insiders have more ownership in AKTS or NAGE?

Do analysts rate AKTS or NAGE?

Summary

How does Niagen Bioscience compare to Xeris Biopharma?

Is NAGE or XERS more profitable?

Do analysts prefer NAGE or XERS?

Do institutionals and insiders hold more shares of NAGE or XERS?

Does the media favor NAGE or XERS?

Which has preferable earnings and valuation, NAGE or XERS?

Which has more risk and volatility, NAGE or XERS?

Summary

How does Niagen Bioscience compare to Evotec?

Do analysts prefer NAGE or EVO?

Which has more risk & volatility, NAGE or EVO?

Which has stronger valuation and earnings, NAGE or EVO?

Is NAGE or EVO more profitable?

Does the media favor NAGE or EVO?

Do insiders and institutionals hold more shares of NAGE or EVO?

Summary

How does Niagen Bioscience compare to Cronos Group?

Which has more volatility and risk, NAGE or CRON?

Do institutionals & insiders believe in NAGE or CRON?

Is NAGE or CRON more profitable?

Do analysts recommend NAGE or CRON?

Does the media prefer NAGE or CRON?

Which has stronger earnings & valuation, NAGE or CRON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAGE vs. The Competition

Niagen Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools